Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up

References

• Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis?. Rheum Dis Clin North Am 1993; 19: 123–51
   PubMed Web of Science ®Google Scholar
• Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 13–22
   PubMedGoogle Scholar
• Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108–11
   PubMed Web of Science ®Google Scholar
• Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993; 32: 717–23
   PubMedGoogle Scholar
• Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39: 616–22
   PubMed Web of Science ®Google Scholar
• Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986–96. J Rheumatol 2001; 28: 2409–15
   PubMedGoogle Scholar
• Capell H, McCarey D, Madhok R, Hampson R. ‘5D’ outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy. J Rheumatol 2002; 29: 2099–105
   PubMedGoogle Scholar
• Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854–60
   PubMed Web of Science ®Google Scholar
• Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–17
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002; 61: 1055–9
   PubMed Web of Science ®Google Scholar
• Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34–45
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792–6
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446–51
   PubMed Web of Science ®Google Scholar
• Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50: 55–62
   PubMed Web of Science ®Google Scholar
• Sokka TM, Kaarela K, Mottonen TT, Hannonen PJ. Conventional monotherapy compared to a ‘sawtooth’ treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999; 17: 527–32
   PubMedGoogle Scholar
• Dale, J, Alcorn, N, Capell, H, Madhok, R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 2007; 3: 450–8, quiz, following 478
   PubMedGoogle Scholar
• Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149–55
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37
   PubMed Web of Science ®Google Scholar
• Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568–73
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–9
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 406–15
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443–9
   PubMed Web of Science ®Google Scholar
• Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis?. Clin Exp Rheumatol 2006; 24: S33–6
   Google Scholar
• Sander O, Herborn G, Bock E, Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann Rheum Dis 1999; 58: 281–7
   Google Scholar
• ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347: 347–52
   PubMed Web of Science ®Google Scholar
• Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175–6
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987; 31: 315–24
   Web of Science ®Google Scholar
• Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the ‘sawtooth’ strategy. J Rheumatol Suppl 1990; 22: 12–15
   PubMedGoogle Scholar
• Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393–406
   PubMedGoogle Scholar
• Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175–84
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308–15
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Hakala M, Nieminen P, Manelius J. Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. J Rheumatol 1994; 21: 64–9
   PubMed Web of Science ®Google Scholar
• Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 481–91
   PubMed Web of Science ®Google Scholar
• ten Wolde S, Hermans J, Breedveld FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997; 56: 235–9
   PubMed Web of Science ®Google Scholar
• Sokka T, Mottonen T, Hannonen P. Disease-modifying anti-rheumatic drug use according to the ‘sawtooth’ treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature. Rheumatology (Oxford) 2000; 39: 34–42
   PubMedGoogle Scholar
• van den Ende CH, Hazes JM, Le Cessie S, Breedveld FC, Dijkmans BA. Discordance between objective and subjective assessment of functional ability of patients with rheumatoid arthritis. Br J Rheumatol 1995; 34: 951–5
   PubMedGoogle Scholar
• Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48: 59–63
   PubMed Web of Science ®Google Scholar
• Tengstrand B, Ahlmen M, Hafstrom I. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 2004; 31: 214–22
   PubMed Web of Science ®Google Scholar
• Thompson PW, Pegley FS. A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br J Rheumatol 1991; 30: 298–300
   PubMedGoogle Scholar
• Paimela L, Laasonen L, Helve T, Leirisalo-Repo M. Comparison of the original and the modified Larsen methods and the Sharp method in scoring radiographic progression in early rheumatoid arthritis. J Rheumatol 1998; 25: 1063–6
   PubMedGoogle Scholar
• Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 611–16
   PubMed Web of Science ®Google Scholar
• Scott DL. Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl 2004; 69: 55–65
   PubMedGoogle Scholar
• Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006; 55: 864–72
   PubMed Web of Science ®Google Scholar